Sumitomo Chemical posted sales of \u00a52.3285 trillion and net income of \u00a56.094 billion for FY2026. Segments such as agrochemicals and pharmaceuticals performed well, with favorable contributions from Sumitomo Pharma’s North American expansion. Outlook for 2027 remains steady.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4005","jir_company_name":"Sumitomo Chemical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-05-14","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4005-20260514-01.pdf","jir_short_summary":"Sumitomo Chemical posted sales of \u00a52.3285 trillion and net income of \u00a56.094 billion for FY2026. Segments such as agrochemicals and pharmaceuticals performed well, with favorable contributions from Sumitomo Pharma's North American expansion. Outlook for 2027 remains steady.","jir_summary":"### Performance Overview\nSumitomo Chemical achieved sales of \u00a52.3285 trillion and net income of \u00a56.094 billion for FY2026. The agrochemical and pharmaceutical segments performed steadily, notably with contributions from Sumitomo Pharma's North American operations. Operating income was \u00a51,517 billion, a decrease compared to the previous term, but net income saw a significant increase. The company plans to continue steady business development and new investments, with a positive outlook for 2027.\n\n### Impact on Shareholders and Future Outlook\nDividends are planned at \u00a57.5 per share for the fiscal year-end, resulting in an annual dividend of \u00a513.5 per share, an increase from previous levels. The 2027 earnings guidance projects sales of \u00a52.36 trillion and net income of \u00a5700 million, with attention to risks such as currency fluctuations and raw material prices. The company intends to actively promote R&D and capital investments, planning to raise approximately \u00a5111.6 billion through new share issuance and stock offerings, focusing on research in oncology and neurodegenerative diseases.","jir_financial_highlights":"Sales Revenue: \u00a52,328,515 million (\u25b310.7% (decrease from the previous term))\nNet Income Attributable to Owners of Parent: \u00a560,947 million (170.3% (increase from the previous term))\nTotal Assets: \u00a53,405,041 million (decrease)","jir_category":"","jir_hashtags":"#SumitomoChemical, #IRResults, #JapanStocks","jir_key_figures":"Sales: \u00a52,328,515 million (YoY \u25b310.7%)\nNet income attributable to owners of parent: \u00a560,947 million (YoY +170.3%)\nTotal assets: \u00a53,405,041 million (decreased)","jir_meta_title":"\u3010Sumitomo Chemical\u3011Financial Results for FY2026 | Sales of \u00a52.33 trillion, Net Income of \u00a56.09 billion | Released on May 14, 2026","jir_meta_description":"Sumitomo Chemical achieved sales of \u00a52.3285 trillion and net income of \u00a56.094 billion for FY2026. Detailed segments performance and future investment plans are explained.","jir_og_title":"\u3010Sumitomo Chemical\u3011Financial Results for FY2026 | Sales of \u00a52.33 trillion, Net Income of \u00a56.09 billion","jir_og_description":"Overview of Sumitomo Chemical's FY2026 financial results and future outlook. Includes key figures like sales, net income, and capital raising plans to inform investors.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7702,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-49885","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n